Skip to main content
Caris Life Sciences8-K: Digital transformation

Caris Life Sciences secures $700M+ in financing, earmarking $300M for future acquisitions.

What happened

The company has secured a $300M delayed draw facility specifically for M&A, signaling a growth-through-acquisition strategy. This creates a significant, near-term need for IT solutions that can handle post-merger integration, data consolidation, and system standardization across acquired entities.

Source

SEC EDGARApr 2, 2026

Current report (Form 8-K)

Caris Life Sciences 8-K

Filing excerpt

The New Credit Agreement provides for certain senior secured credit facilities to the Company consisting of (a) an initial term loan in an aggregate principal amount equal to $400,000,000, funded on the Closing Date (the “Initial Term Facility”), (b) a committed delayed draw term loan facility in an aggregate principal amount that may be drawn in one or more tranches not to exceed $300,000,000 in the aggregate (“Delayed Draw Facility”)...

sec.gov/Archives/edgar/data/2019410/000201941026000019/cai-20260401.htmRead the full source

Other signals in this filing (2)

Extracted by Autobound

From the Signal API record
Signal
8-K: Digital transformation

What this signalsFilings often name leadership changes, deals and spending plans.

Form
8-K
Fiscal year end
04/01
Filed
Apr 2, 2026

The full record

From the Signal API record

Numbers

Dollar figure
$700M (Total committed capital from new credit facility, including a $400M initial term loan and a $300M delayed draw facility reserved for acquisitions.)

Details

CIK
2019410
Accession number
0002019410-26-000019
Timeframe
Immediate
Filing year
2026
Why it matters
Multi-year tech investment
Signal category
Strategic

Topics and mentions

Vendors

  • Blue Owl Capital
  • Blackstone
  • Wilmington Trust
  • National Association

Vendors named

  • Blue Owl Capital
  • Blackstone
  • Wilmington Trust, National Association

Extraction

Confidence
High
Relevance
85%
Sentiment
Positive
Detected
Apr 7, 2026
signal_type
sec-8k
signal_subtype
digitalTransformation

Use this data

Get every 8-K signal for Caris Life Sciences and the companies you sell to, in the tools you already use.

  1. Ask Claude about it

    Connect Autobound to Claude, Claude Code or Cursor with MCP. Then ask: “What changed at Caris Life Sciences this week?”

  2. Send it to your own tools

    The Signal API returns 8-K signals for any list of companies as JSON, for your CRM, warehouse or app.

  3. Try it free

    Sign up and spend your free credits on the companies you sell to.

    Start Free1,000 free credits

The API returns more than this page shows

This page shows a preview. The full sec-8k record in the Signal API and MCP can also have these 8 fields. Some fields are empty for some signals.

Company

  • linkedin_urlValue in the API
  • industriesValue in the API
  • employee_count_lowValue in the API
  • employee_count_highValue in the API
  • revenueValue in the API
  • descriptionValue in the API

Signal

  • signal_nameValue in the API
  • associationValue in the API
Show the full JSONThe record on this page and the API request

GET /v1/signals/124bdbeb-2f83-44b3-b9d2-adeb49ee5e6b returns this record as JSON. POST /v1/companies/enrich returns every signal for carislifesciences.com.

{
  "signal_id": "124bdbeb-2f83-44b3-b9d2-adeb49ee5e6b",
  "signal_type": "sec-8k",
  "signal_subtype": "digitalTransformation",
  "detected_at": "2026-04-07T09:30:39.547+00:00",
  "company": {
    "name": "Caris Life Sciences",
    "domain": "carislifesciences.com"
  },
  "data": {
    "detail": "The company has secured a $300M delayed draw facility specifically for M&A, signaling a growth-through-acquisition strategy. This creates a significant, near-term need for IT solutions that can handle post-merger integration, data consolidation, and system standardization across acquired entities.",
    "metrics": {
      "timeframe": "immediate",
      "dollar_context": "Total committed capital from new credit facility, including a $400M initial term loan and a $300M delayed draw facility reserved for acquisitions.",
      "dollar_millions": 700
    },
    "summary": "Caris Life Sciences secures $700M+ in financing, earmarking $300M for future acquisitions.",
    "excerpts": "The New Credit Agreement provides for certain senior secured credit facilities to the Company consisting of (a) an initial term loan in an aggregate principal amount equal to $400,000,000, funded on the Closing Date (the “Initial Term Facility”), (b) a committed delayed draw term loan facility in an aggregate principal amount that may be drawn in one or more tranches not to exceed $300,000,000 in the aggregate (“Delayed Draw Facility”)...",
    "relevance": 0.85,
    "sentiment": "positive",
    "confidence": "high",
    "source_url": "https://www.sec.gov/Archives/edgar/data/2019410/000201941026000019/cai-20260401.htm",
    "filing_date": "2026-04-02",
    "filing_year": 2026,
    "fiscal_year_end": "04/01",
    "sales_relevance": "Multi-year tech investment",
    "signal_category": "strategic",
    "vendors_mentioned": [
      "Blue Owl Capital",
      "Blackstone",
      "Wilmington Trust, National Association"
    ]
  }
}

Long text fields are shortened on this page.

Looking up one signal by its id is free. Enrich costs 2 credits per signal returned; a call with no results is free.